Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003 | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003	Abnormalities, Multiple, Ciliopathies, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, autosomal dominant polycystic kidney disease, cystic kidney disease, hereditary disease, kidney disorder, polycystic kidney disease, urinary system disorder	Recruiting	Phase 1	2026-07-27		NCT06714006

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
PYC Therapeutics	5

12 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Concord Repatriation General Hospital	Concord	Australia	39
Linear Clinical Research	Joondalup	Australia	1
Liverpool Hospital, Clinic G-Reception 133, Level 1, Clinical Building, Burnside Drive	Liverpool	Australia	1
Mater Hospital Brisbane	South Brisbane	Australia	10
Pacific Clinical Research Network Auckland	Takapuna	New Zealand	2
Prince of Wales Hospital	Shatin	Hong Kong	14
Scientia Clinical Research	Randwick	Australia	20
South Coast Renal, Brockway House, Level 1, Suite 8, 82-86 Queen Street,	Southport	Australia	1
St Vincent's Hospital Melbourne	Fitzroy	Australia	1
Sunshine Hospital, Western Centre for Health Research and Education, Level 3, 176-190 Furlong Road	Saint Albans	Australia	1
Sydney Adventist Hospital	Wahroonga	Australia	17
Westmead Hospital, Clinical Research Unit, Level 6, B Wing/Building, Hawkesbury Road	Westmead	Australia	1